NRT briefing
FDA inspectors found bugs, mold at two Chinese factories that make GLP-1 weight-loss drugs: report
Based on reporting by New York Post.
The Brief
FDA inspectors found "gross contamination," including mold and bug infestations, at two Chinese factories that make components for GLP-1 weight-loss drugs, according to a Bloomberg report. The facilities, operated by Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co., supplied semaglutide and tirzepatide — the active ingredients in Novo Nordisk's and Eli Lilly's weight-loss drugs — for black-market versions not approved by regulators.
At the Chengdu facility, inspectors found bugs in the ceiling and moldy floors, and employees appeared to pour product samples into sinks and hurriedly move documents into lockers in a "seemingly coordinated effort." At the Nanjing facility, staff reportedly bought active ingredients from other factories and applied their own seal of approval without reviewing testing and safety documentation.
Both companies were placed on the FDA's import list, allowing confiscation of their products at the border. The drugs themselves were not tested. Chengdu Shengnuo said in a Chinese government filing that it was "diligently implementing effective measures" to correct the problems.
Michael Rogers, a former FDA investigator, told Bloomberg the findings "suggest a serious accident waiting to happen." The FDA is considering allowing overseas compounding pharmacies to produce other peptides, while Health Secretary Robert F. Kennedy has supported lifting restrictions on them.
The report notes that contaminated drugs from New England Compounding Pharmacy killed 64 people nearly fifteen years ago.
NRT commentary
How We See It
The FDA's findings of mold, bugs, and document shuffling at Chinese factories producing GLP-1 ingredients should alarm anyone using or considering compounded weight-loss drugs. The black-market peptide industry operates in a regulatory gray area, and these inspections reveal what can happen when oversight is weak.
The FDA's import ban is a good first step, but the agency must go further to ensure that unapproved copycats don't reach American patients. Health Secretary Robert F. Kennedy's support for lifting peptide restrictions is concerning in this light; deregulation without robust safety checks could repeat the tragedy of the New England Compounding Pharmacy meningitis outbreak that killed 64 people.
The multibillion-dollar peptide industry needs transparency and accountability, not loopholes that endanger lives. Consumers should stick to FDA-approved medications unless they have clear evidence of safety and quality.
Commentary uses AI assistance. What is How We See It? Read about our automated checks or report a correction.